Načítá se...
Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease in industrialized economies. With no licensed treatment currently available, together with a growing prevalence that parallels global increases in obesity and type 2 diabetes, NAFLD will dominate the landscape...
Uloženo v:
| Vydáno v: | J Clin Exp Hepatol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6728526/ https://ncbi.nlm.nih.gov/pubmed/31516268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2019.03.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|